PT88115A - Dna constructs containing a kluyveromyces alpha-factor leader sequence for directing secretion of heterologous polypetides - Google Patents

Dna constructs containing a kluyveromyces alpha-factor leader sequence for directing secretion of heterologous polypetides

Info

Publication number: PT88115A
Authority: PT; Portugal
Prior art keywords: heterologous; factor leader; leader sequence; polypetides; dna constructs
Prior art date: 1987-07-28

Application number

PT88115A

Other languages

English (en)

Other versions

PT88115B (pt

Inventor

Anthony J Brake

Johannes A Van Den Berg

Original Assignee

Gist Brocades Nv

Chiron Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-07-28

Filing date

1988-07-27

Publication date

1989-06-30

1988-07-27 Application filed by Gist Brocades Nv, Chiron Corp filed Critical Gist Brocades Nv

1989-06-30 Publication of PT88115A publication Critical patent/PT88115A/pt

1995-03-01 Publication of PT88115B publication Critical patent/PT88115B/pt

Links

IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 title abstract 3
241000235649 Kluyveromyces Species 0.000 title abstract 2
230000028327 secretion Effects 0.000 title 1
240000004808 Saccharomyces cerevisiae Species 0.000 abstract 2
229920001184 polypeptide Polymers 0.000 abstract 2
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
102000004196 processed proteins & peptides Human genes 0.000 abstract 2
108020004414 DNA Proteins 0.000 abstract 1
241001138401 Kluyveromyces lactis Species 0.000 abstract 1
108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
108010064037 prorennin Proteins 0.000 abstract 1
230000003248 secreting effect Effects 0.000 abstract 1
125000006850 spacer group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6478—Aspartic endopeptidases (3.4.23)
- C12N9/6481—Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Mycology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Medicinal Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Saccharide Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Enzymes And Modification Thereof (AREA)

PT88115A 1987-07-28 1988-07-27 Processo para a preparacao de construcoes de adn que contem uma sequencia guia do factor de kluyveromyces, de vectores de expressao que contem estas construcoes e de polipeptideos codificados por este adn PT88115B (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/078,551 US5010182A (en)	1987-07-28	1987-07-28	DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides

Publications (2)

Publication Number	Publication Date
PT88115A true PT88115A (pt)	1989-06-30
PT88115B PT88115B (pt)	1995-03-01

Family

ID=22144759

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT88115A PT88115B (pt)	1987-07-28	1988-07-27	Processo para a preparacao de construcoes de adn que contem uma sequencia guia do factor de kluyveromyces, de vectores de expressao que contem estas construcoes e de polipeptideos codificados por este adn

Country Status (19)

Country	Link
US (1)	US5010182A (pt)
EP (1)	EP0301669B1 (pt)
JP (1)	JP2680054B2 (pt)
KR (1)	KR970004940B1 (pt)
CN (1)	CN1045620C (pt)
AT (1)	ATE90727T1 (pt)
AU (1)	AU623860B2 (pt)
CA (1)	CA1327762C (pt)
DE (1)	DE3881776T2 (pt)
DK (1)	DK175365B1 (pt)
ES (1)	ES2058238T3 (pt)
FI (1)	FI101232B1 (pt)
HU (1)	HU213015B (pt)
IE (1)	IE62261B1 (pt)
IL (1)	IL87255A (pt)
NO (1)	NO180381C (pt)
NZ (1)	NZ225596A (pt)
PT (1)	PT88115B (pt)
ZA (1)	ZA885535B (pt)

Families Citing this family (161)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1340772C (en)	1987-12-30	1999-09-28	Patricia Tekamp-Olson	Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
DE68928124T2 (de)	1988-09-02	1997-10-16	Chiron Corp., Emeryville, Calif.	Makrophagenabgeleiteter entzündungsmediator(mip-2)
GB9015825D0 (en) *	1990-07-18	1990-09-05	Ciba Geigy Ag	In vitro processing of fusion proteins
US6040172A (en) *	1992-08-14	2000-03-21	The Rockefeller University	Defective DNA viral vector comprising a neural tissue-specific promoter for in vivo expression of a gene
US6500645B1 (en)	1994-06-17	2002-12-31	Novo Nordisk A/S	N-terminally extended proteins expressed in yeast
ZA954983B (en) *	1994-06-17	1996-02-14	Novo Nordisk As	N-terminally extended proteins expressed in yeast
US6998116B1 (en)	1996-01-09	2006-02-14	Genentech, Inc.	Apo-2 ligand
US6030945A (en) *	1996-01-09	2000-02-29	Genentech, Inc.	Apo-2 ligand
US6046048A (en) *	1996-01-09	2000-04-04	Genetech, Inc.	Apo-2 ligand
US20050089958A1 (en) *	1996-01-09	2005-04-28	Genentech, Inc.	Apo-2 ligand
WO1997037020A1 (en)	1996-04-01	1997-10-09	Genentech, Inc.	Apo-2li and apo-3 apoptosis polypeptides
US20020165157A1 (en) *	1996-04-01	2002-11-07	Genentech, Inc.	Apo-2LI and Apo-3 polypeptides
US5851984A (en) *	1996-08-16	1998-12-22	Genentech, Inc.	Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6159462A (en) *	1996-08-16	2000-12-12	Genentech, Inc.	Uses of Wnt polypeptides
US6462176B1 (en)	1996-09-23	2002-10-08	Genentech, Inc.	Apo-3 polypeptide
WO1999047677A2 (en)	1998-03-17	1999-09-23	Genentech, Inc.	Polypeptides homologous to vegf and bmp1
US20020102706A1 (en) *	1997-06-18	2002-08-01	Genentech, Inc.	Apo-2DcR
US6265186B1 (en)	1997-04-11	2001-07-24	Dsm N.V.	Yeast cells comprising at least two copies of a desired gene integrated into the chromosomal genome at more than one non-ribosomal RNA encoding domain, particularly with Kluyveromyces
ES2293682T5 (es) *	1997-05-15	2011-11-17	Genentech, Inc.	Anticuerpo anti-apo2.
US20100152426A1 (en) *	1997-05-15	2010-06-17	Ashkenazi Avi J	Apo-2 receptor fusion proteins
US6342369B1 (en) *	1997-05-15	2002-01-29	Genentech, Inc.	Apo-2-receptor
JP2001523977A (ja)	1997-06-05	2001-11-27	ザユニバーシティオブテキサスシステムボードオブリージェンツ	Ａｐａｆ−１、ｃｅｄ−４ヒト相同体、カスパーゼ−３の活性化因子
AU740227B2 (en) *	1997-06-18	2001-11-01	Genentech Inc.	Apo-2DcR
US20030175856A1 (en) *	1997-08-26	2003-09-18	Genetech, Inc.	Rtd receptor
ES2331900T3 (es) *	1997-08-26	2010-01-19	Genentech, Inc.	Receptor rtd.
US20040231011A1 (en) *	2001-06-28	2004-11-18	Genentech, Inc.	DcR3 polypeptide, a TNFR homolog
ATE393222T1 (de) *	1997-09-18	2008-05-15	Genentech Inc	Dcr3 polypeptid, ein tnfr homolog
CA2305713A1 (en)	1997-10-10	1999-04-22	Genentech, Inc.	Apo-3 ligand
DK1027437T3 (da)	1997-10-29	2008-11-24	Genentech Inc	Anvendelse af det WNT-1 inducerede udskilte polypeptid WISP-1
EP1029046B1 (en)	1997-10-29	2008-09-24	Genentech, Inc.	Wnt-1 inducible genes
US7192589B2 (en)	1998-09-16	2007-03-20	Genentech, Inc.	Treatment of inflammatory disorders with STIgMA immunoadhesins
ES2305608T3 (es)	1997-11-21	2008-11-01	Genentech, Inc.	Antigenos tipo a-33 y sus utilizaciones farmacologicas.
JP2002508962A (ja)	1998-01-15	2002-03-26	ジェネンテク・インコーポレイテッド	Ａｐｏ−２リガンド
US6727079B1 (en)	1998-02-25	2004-04-27	The United States Of America As Represented By The Department Of Health And Human Services	cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product
EP2050762A3 (en)	1998-03-10	2009-07-08	Genentech, Inc.	Human cornichon-like protein and nucleic acids encoding it
NZ508878A (en)	1998-05-15	2003-08-29	Genentech Inc	IL-17B and IL-17Cactive variants of IL-17 which stimulates epithelial, endothelial and fibroblastic cells
EP1865061A3 (en)	1998-05-15	2007-12-19	Genentech, Inc.	IL-17 homologous polypeptides and therapeutic uses thereof
EP3112468A1 (en)	1998-05-15	2017-01-04	Genentech, Inc.	Il-17 homologous polypeptides and therapeutic uses thereof
EP1086138B1 (en) *	1998-06-12	2009-09-23	Genentech, Inc.	Monoclonal antibodies, cross-reactive antibodies and method for producing the same
US20020172678A1 (en)	2000-06-23	2002-11-21	Napoleone Ferrara	EG-VEGF nucleic acids and polypeptides and methods of use
EP2319929A1 (en)	1998-12-23	2011-05-11	Genentech, Inc.	IL-1 related polypeptides
EP1956030B1 (en)	1999-06-15	2009-11-11	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids endoding the same
AU1095001A (en)	1999-10-20	2001-04-30	Genentech Inc.	Type i cytokine receptor tccr
EP1686134A3 (en)	1999-12-01	2006-08-09	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1897945B1 (en)	1999-12-23	2012-01-18	Genentech, Inc.	IL-17 homologous polypeptides and therapeutic uses thereof
KR20020073491A (ko)	1999-12-30	2002-09-26	제넨코 인터내셔날 인코포레이티드	트리코데르마 레제이 자일란 분해효소
ATE424457T1 (de) *	2000-01-13	2009-03-15	Genentech Inc	Menschliche stra6 polypeptide
US6992081B2 (en)	2000-03-23	2006-01-31	Elan Pharmaceuticals, Inc.	Compounds to treat Alzheimer's disease
ATE343562T1 (de) *	2000-03-23	2006-11-15	Elan Pharm Inc	Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
ATE394496T1 (de) *	2000-03-24	2008-05-15	Genencor Int	Herstellung von sekretierten proteinen durch rekombinante eukaryotische zellen
EP2275549A1 (en)	2000-06-23	2011-01-19	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2648048A1 (en)	2000-06-23	2002-01-03	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP1299352B1 (en)	2000-06-30	2005-12-28	Elan Pharmaceuticals, Inc.	Compounds to treat alzheimer's disease
PE20020276A1 (es)	2000-06-30	2002-04-06	Elan Pharm Inc	COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US20030096864A1 (en) *	2000-06-30	2003-05-22	Fang Lawrence Y.	Compounds to treat alzheimer's disease
US6846813B2 (en) *	2000-06-30	2005-01-25	Pharmacia & Upjohn Company	Compounds to treat alzheimer's disease
DE60136281D1 (de)	2000-08-24	2008-12-04	Genentech Inc	Methode zur inhibierung von il-22 induziertem pap1
EP1944317A3 (en)	2000-09-01	2008-09-17	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6673580B2 (en) *	2000-10-27	2004-01-06	Genentech, Inc.	Identification and modification of immunodominant epitopes in polypeptides
US20070160576A1 (en)	2001-06-05	2007-07-12	Genentech, Inc.	IL-17A/F heterologous polypeptides and therapeutic uses thereof
CA2633595A1 (en)	2001-06-20	2003-01-03	Genentech, Inc.	Antibodies against tumor-associated antigenic target (tat) polypeptides
US6982264B2 (en) *	2001-06-27	2006-01-03	Elan Pharmaceuticals, Inc.	Substituted alcohols useful in treatment of Alzheimer's disease
KR101008734B1 (ko) *	2001-08-29	2011-01-14	제넨테크, 인크.	유사분열촉진 활성을 가진 Ｂｖ８ 핵산 및 폴리펩티드
KR101008758B1 (ko)	2001-09-18	2011-01-14	제넨테크, 인크.	종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
KR100801388B1 (ko)	2002-01-02	2008-02-05	제넨테크, 인크.	종양의 진단 및 치료 방법 및 이를 위한 조성물
WO2003072035A2 (en)	2002-02-22	2003-09-04	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
NZ535925A (en)	2002-04-16	2008-06-30	Genentech Inc	An isolated antibody that binds to a particular polypeptide
EP2305710A3 (en)	2002-06-03	2013-05-29	Genentech, Inc.	Synthetic antibody phage libraries
EP1553912A4 (en) *	2002-06-07	2007-08-08	Genentech Inc	COMPOSITIONS AND METHODS FOR TUMOR DIAGNOSIS AND TREATMENT
WO2004004649A2 (en)	2002-07-08	2004-01-15	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
WO2007068784A1 (en)	2005-12-14	2007-06-21	Licentia Ltd	Novel neurotrophic factor protein and uses thereof
JP2006521082A (ja)	2002-09-11	2006-09-21	ジェネンテック・インコーポレーテッド	免疫関連疾患の治療のための新規組成物と方法
ES2357505T3 (es)	2002-09-11	2011-04-27	Genentech, Inc.	Composición y procedimientos novedosos para el tratamiento de enfermedades inmunorelacionadas.
JP2006515165A (ja)	2002-09-16	2006-05-25	ジェネンテック・インコーポレーテッド	免疫関連疾患の治療のための新規組成物と方法
EP2500438A3 (en)	2002-09-25	2012-11-28	Genentech, Inc.	Novel compositions and methods for the treatment of psoriasis
EP2322203A3 (en)	2002-10-29	2011-07-27	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
EP2364716A3 (en)	2002-11-08	2012-01-11	Genentech, Inc.	Compositions and methods for the treatment of natural killer cell related diseases
WO2004047728A2 (en)	2002-11-26	2004-06-10	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
US7118901B2 (en)	2002-12-18	2006-10-10	Roche Diagnostics Operations, Inc.	Recombinant bovine pancreatic desoxyribonuclease I with high specific activity
JP4912144B2 (ja)	2003-03-12	2012-04-11	ジェネンテック，インコーポレイテッド	造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用
DK1610820T4 (da)	2003-04-04	2013-11-04	Genentech Inc	Høj-koncentration antistof- og proteinformuleringer
CA2528591C (en)	2003-06-12	2013-01-08	Eli Lilly And Company	Glp-1 analog fusion proteins
EP1641822B1 (en)	2003-07-08	2013-05-15	Genentech, Inc.	Il-17 a/f heterologous polypeptides and therapeutic uses thereof
WO2005019258A2 (en)	2003-08-11	2005-03-03	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
DE10342794A1 (de) *	2003-09-16	2005-04-21	Basf Ag	Sekretion von Proteinen aus Hefen
NZ596984A (en)	2003-11-17	2013-10-25	Genentech Inc	Compositions and methods for the treatment of tumor of hematopoietic origin
DE602004031881D1 (de) *	2003-12-19	2011-04-28	Univ California	Verfahren und materialien zur beurteilung von prostatakrebstherapien
WO2005099693A2 (en) *	2004-02-24	2005-10-27	The Regents Of The University Of California	Methods and materials for assessing prostate cancer therapies and compounds
US7709517B2 (en) *	2005-05-13	2010-05-04	The Regents Of The University Of California	Diarylhydantoin compounds
CA2610709A1 (en)	2005-06-06	2006-12-14	Genentech, Inc.	Transgenic models for different genes and their use for gene characterization
ZA200800970B (en)	2005-08-15	2009-10-28	Genentech Inc	Gene disruptions, compositions and methods relating thereto
JP4860702B2 (ja) *	2005-10-21	2012-01-25	エフ．ホフマン−ラロシュアーゲー	ポリペプチドのリコンビナント発現のための方法
EP1962584A2 (en)	2005-11-21	2008-09-03	Genentech, Inc.	Novel gene disruptions, compositions and methods relating thereto
US20080311107A1 (en)	2006-02-17	2008-12-18	Genetech, Inc.	Novel Gene Disruptions, Compositions and Methods Relating Thereto
PL3412290T3 (pl)	2006-03-27	2021-09-06	The Regents Of The University Of California	Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym
CA2648139A1 (en) *	2006-03-29	2007-11-08	The Regents Of The University Of California	Diaryl thiohydantoin compounds and their use in the treatment of hyperproliferative disorders
EP2614839A3 (en)	2006-04-05	2015-01-28	Genentech, Inc.	Method for using BOC/CDO to modulate hedgehog signaling
CA2649387A1 (en)	2006-04-19	2008-03-27	Genentech, Inc.	Novel gene disruptions, compositions and methods relating thereto
JP2010507381A (ja) *	2006-10-24	2010-03-11	ノボザイムスアクティーゼルスカブ	ポリペプチド製造用の改良されたα因子シグナル・ペプチド
CN101965363A (zh) *	2006-11-02	2011-02-02	丹尼尔·J·卡鹏	具有活动部分的杂合免疫球蛋白
NZ578980A (en)	2007-02-22	2012-03-30	Genentech Inc	Methods for detecting inflammatory bowel disease
RU2557319C2 (ru)	2007-07-16	2015-07-20	Дженентек, Инк.	ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ
MY150531A (en)	2007-07-16	2014-01-30	Genentech Inc	Anti-cd79b antibodies and immunoconjugates and methods of use
CN101361968B (zh)	2007-08-06	2011-08-03	健能隆医药技术（上海）有限公司	白介素-22在治疗脂肪肝中的应用
US8771988B2 (en)	2007-10-12	2014-07-08	Hoffmann-La Roche Inc.	Protein expression from multiple nucleic acids
US8680291B2 (en)	2007-10-26	2014-03-25	The Regents Of The University Of California	Diarylhydantoin compounds
DK2657253T3 (en)	2008-01-31	2017-10-09	Genentech Inc	Anti-CD79b antibodies and immune conjugates and methods of use
MX2010011088A (es)	2008-04-09	2010-11-05	Genentech Inc	Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
CR20170001A (es)	2008-04-28	2017-08-10	Genentech Inc	Anticuerpos anti factor d humanizados
FI20080326A0 (fi)	2008-04-30	2008-04-30	Licentia Oy	Neurotroofinen tekijä MANF ja sen käytöt
SG174992A1 (en)	2009-04-01	2011-11-28	Genentech Inc	Anti-fcrh5 antibodies and immunoconjugates and methods of use
EP2258855A1 (en)	2009-05-28	2010-12-08	Universität für Bodenkultur Wien	Expression sequences
KR101952453B1 (ko) *	2009-10-15	2019-02-26	제넨테크, 인크.	수용체 특이성이 변경된 키메라 섬유모세포 성장 인자
CA2778442A1 (en)	2009-10-22	2011-04-28	Genentech, Inc.	Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
WO2011056502A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056494A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor type iib compositions and methods of use
JP2013510871A (ja)	2009-11-12	2013-03-28	ジェネンテック，インコーポレイテッド	樹状突起棘の密度を促す方法
AU2010324686B2 (en)	2009-11-30	2016-05-19	Genentech, Inc.	Antibodies for treating and diagnosing tumors expressing SLC34A2 (TAT211 = SEQID2 )
EA028869B1 (ru)	2010-02-16	2018-01-31	Арагон Фармасьютикалс, Инк.	Модуляторы рецептора андрогенов и их применение
MX2012009215A (es)	2010-02-23	2012-11-23	Genentech Inc	Composiciones y metodos para el diagnostico y tratamiento de tumores.
MX342239B (es)	2010-05-03	2016-09-21	Genentech Inc *	Composiciones y metodos para el diagnostico y tratamiento de tumores.
EP2585094B1 (en)	2010-06-25	2018-08-01	INSERM - Institut National de la Santé et de la Recherche Médicale	Flagellin polypeptide as tlr5 agonist for use in the treatment of respiratory tract infections
CN102380091A (zh)	2010-08-31	2012-03-21	健能隆医药技术（上海）有限公司	白介素-22在治疗病毒性肝炎中的应用
AU2011302522A1 (en)	2010-09-15	2013-05-02	Aligna Technologies, Inc.	Bioproduction of aromatic chemicals from lignin-derived compounds
SG10201608341XA (en)	2011-11-23	2016-11-29	Hoffmann La Roche	Cd40l expressing mammalian cells and their use
EP2839011B1 (en)	2012-04-17	2016-09-14	F. Hoffmann-La Roche AG	Method for the expression of polypeptides using modified nucleic acids
PT3305285T (pt)	2012-09-26	2020-11-24	Aragon Pharmaceuticals Inc	Antiandrogénios para o tratamento de cancro da próstata resistente à castração não metastático
AU2013341049B2 (en)	2012-10-29	2017-07-20	Lonza Ltd	Expression sequences
WO2014088934A1 (en)	2012-12-07	2014-06-12	Danisco Us Inc.	Compositions and methods of use
EP2929021A1 (en)	2012-12-07	2015-10-14	Danisco US Inc.	Compositions and methods of use
JOP20200097A1 (ar)	2013-01-15	2017-06-16	Aragon Pharmaceuticals Inc	معدل مستقبل أندروجين واستخداماته
DK2968495T3 (da)	2013-03-15	2019-10-14	Daniel J Capon	Hybrid immunoglobulin indeholdende en ikke-peptid-bro
EA035645B1 (ru)	2013-03-15	2020-07-21	Дженентек, Инк.	ПОЛИПЕПТИДЫ IL-22, ХИМЕРНЫЕ БЕЛКИ IL-22 Fc И ИХ ПРИМЕНЕНИЕ
US20160075766A1 (en)	2013-05-21	2016-03-17	Roche Diagnostics Operations, Inc.	Method for producing antibodies using ovine b-cells and uses thereof
CN104623637A (zh)	2013-11-07	2015-05-20	健能隆医药技术（上海）有限公司	Il-22二聚体在制备静脉注射药物中的应用
LT3116486T (lt)	2014-03-14	2020-04-10	Biomolecular Holdings Llc	Hibridinis imunoglobulinas, turintis nepetidilinę jungtį
WO2016054185A1 (en)	2014-09-30	2016-04-07	Danisco Us Inc	Compositions comprising beta-mannanase and methods of use
WO2016054205A1 (en)	2014-09-30	2016-04-07	Danisco Us Inc	Compositions comprising beta mannanase and methods of use
US20170226494A1 (en)	2014-09-30	2017-08-10	Danisco Us Inc.	Compositions comprising beta-mannanase and methods of use
WO2016054168A1 (en)	2014-09-30	2016-04-07	Danisco Us Inc	Compositions comprising beta mannanase and methods of use
EP3201334A1 (en)	2014-09-30	2017-08-09	Danisco US Inc.	Compositions comprising beta-mannanase and methods of use
WO2016100825A1 (en)	2014-12-18	2016-06-23	Danisco Us Inc	Engineered multifunctional enzymes and methods of use
WO2016100837A1 (en)	2014-12-18	2016-06-23	Danisco Us Inc	Engineered multifunctional enzymes and methods of use
TWI726969B (zh)	2016-01-11	2021-05-11	比利時商健生藥品公司	用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
EP4273232A3 (en)	2016-03-30	2024-01-03	F. Hoffmann-La Roche AG	B-cell cultivation method
EP3442562B1 (en)	2016-04-15	2022-09-21	Evive Biotechnology (Shanghai) Ltd	An il-22 dimer for use in treating necrotizing enterocolitis
EP3562936B1 (en)	2017-01-02	2024-05-22	F. Hoffmann-La Roche AG	B-cell cultivation method
WO2018152496A1 (en)	2017-02-17	2018-08-23	The Usa, As Represented By The Secretary, Dept. Of Health And Human Services	Compositions and methods for the diagnosis and treatment of zika virus infection
WO2018200742A1 (en)	2017-04-25	2018-11-01	The Usa, As Represented By The Secretary, Dept. Of Health And Human Services	Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
JP6978516B2 (ja)	2017-05-19	2021-12-08	エフ.ホフマン−ラロシュアーゲーF. Hoffmann−La Roche Aktiengesellschaft	胸腺細胞上清を産生するための方法
CN109022478A (zh) *	2017-06-09	2018-12-18	康码（上海）生物科技有限公司	一种用于高通量体外蛋白质合成的dna元件
EP3655430A1 (en)	2017-07-19	2020-05-27	The U.S.A. as represented by the Secretary, Department of Health and Human Services	Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
EP4438126A3 (en)	2017-10-16	2025-01-01	Aragon Pharmaceuticals, Inc.	Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CR20200327A (es)	2018-01-26	2020-11-05	Genentech Inc	Proteínas de fusión fc il-22 y métodos de uso
HRP20221448T1 (hr)	2018-01-26	2023-01-20	F. Hoffmann - La Roche Ag	Il-22 fc pripravci i postupci njihove primjene
CN111757751A (zh)	2018-02-21	2020-10-09	豪夫迈·罗氏有限公司	用于使用IL-22 Fc融合蛋白的治疗的剂量方案
US12084489B2 (en)	2018-05-02	2024-09-10	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antibodies and methods for the diagnosis, prevention, and treatment of Epstein Barr virus infection
BR112021025806A2 (pt)	2019-06-28	2022-02-08	Hoffmann La Roche	Métodos para produzir um anticorpo da subclasse igg1 humana cultivando uma célula cho e uso da remoção de sítios de splice de doador não pareados em uma parte de uma sequência de ácido nucleico de humano ou hamster
WO2021207662A1 (en)	2020-04-10	2021-10-14	Genentech, Inc.	Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
EP4577578A1 (en)	2022-08-22	2025-07-02	Abdera Therapeutics Inc.	Dll3 binding molecules and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3382547D1 (de) *	1983-01-12	1992-05-27	Chiron Corp	Sekretorische expression in eukaryoten.
NZ207926A (en) *	1983-04-25	1988-04-29	Genentech Inc	Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
AU2722184A (en) *	1983-04-25	1984-11-01	Genentech Inc.	Use of alpha sequences in yeast expression systems
JPS6156078A (ja) *	1984-07-27	1986-03-20	Suntory Ltd	酵母を宿主とする分泌発現ベクタ−
IE62458B1 (en) *	1987-07-28	1995-02-08	Gist Brocades Nv	Kluyveromyces as a host strain
CA1340772C (en) *	1987-12-30	1999-09-28	Patricia Tekamp-Olson	Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences

1987
- 1987-07-28 US US07/078,551 patent/US5010182A/en not_active Expired - Lifetime
1988
- 1988-07-27 PT PT88115A patent/PT88115B/pt not_active IP Right Cessation
- 1988-07-28 AT AT88201631T patent/ATE90727T1/de not_active IP Right Cessation
- 1988-07-28 KR KR1019880009541A patent/KR970004940B1/ko not_active Expired - Fee Related
- 1988-07-28 NO NO883346A patent/NO180381C/no not_active IP Right Cessation
- 1988-07-28 NZ NZ225596A patent/NZ225596A/en unknown
- 1988-07-28 HU HU884021A patent/HU213015B/hu unknown
- 1988-07-28 DK DK198804222A patent/DK175365B1/da not_active IP Right Cessation
- 1988-07-28 IL IL87255A patent/IL87255A/xx not_active IP Right Cessation
- 1988-07-28 DE DE88201631T patent/DE3881776T2/de not_active Expired - Lifetime
- 1988-07-28 FI FI883541A patent/FI101232B1/fi active IP Right Grant
- 1988-07-28 IE IE231388A patent/IE62261B1/en not_active IP Right Cessation
- 1988-07-28 JP JP63189552A patent/JP2680054B2/ja not_active Expired - Lifetime
- 1988-07-28 AU AU20136/88A patent/AU623860B2/en not_active Expired
- 1988-07-28 ZA ZA885535A patent/ZA885535B/xx unknown
- 1988-07-28 CN CN88104680A patent/CN1045620C/zh not_active Expired - Lifetime
- 1988-07-28 ES ES88201631T patent/ES2058238T3/es not_active Expired - Lifetime
- 1988-07-28 EP EP88201631A patent/EP0301669B1/en not_active Expired - Lifetime
- 1988-07-28 CA CA000573342A patent/CA1327762C/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
HUT47638A (en)	1989-03-28
FI883541A0 (fi)	1988-07-28
DE3881776T2 (de)	1993-11-18
PT88115B (pt)	1995-03-01
AU2013688A (en)	1989-02-02
US5010182A (en)	1991-04-23
NO883346D0 (no)	1988-07-28
DK422288D0 (da)	1988-07-28
HU213015B (en)	1997-01-28
IE62261B1 (en)	1995-01-11
NO883346L (no)	1989-01-30
EP0301669A1 (en)	1989-02-01
NZ225596A (en)	1991-04-26
KR890002406A (ko)	1989-04-10
IE882313L (en)	1989-01-28
IL87255A (en)	1993-04-04
DK422288A (da)	1989-01-29
CN1032367A (zh)	1989-04-12
FI883541L (fi)	1989-01-29
FI101232B (fi)	1998-05-15
KR970004940B1 (ko)	1997-04-10
JPH01124390A (ja)	1989-05-17
NO180381C (no)	1997-04-09
IL87255A0 (en)	1988-12-30
CA1327762C (en)	1994-03-15
FI101232B1 (fi)	1998-05-15
NO180381B (no)	1996-12-30
DK175365B1 (da)	2004-09-13
ES2058238T3 (es)	1994-11-01
EP0301669B1 (en)	1993-06-16
ZA885535B (en)	1989-04-26
DE3881776D1 (de)	1993-07-22
CN1045620C (zh)	1999-10-13
AU623860B2 (en)	1992-05-28
JP2680054B2 (ja)	1997-11-19
ATE90727T1 (de)	1993-07-15

Publication	Publication Date	Title
PT88115A (pt)	1989-06-30	Dna constructs containing a kluyveromyces alpha-factor leader sequence for directing secretion of heterologous polypetides
EP0396612A4 (en)	1991-10-02	Novel plasmid vector with pectate lyase signal sequence
FI901428A0 (fi)	1990-03-21	Peptid och dna-sekvenser.
IE820069L (en)	1983-06-01	Recombinant dna encoding a polypeptide
IL87366A (en)	1993-08-18	Decay-accelerating factor (daf) polypeptide dna fusions to dna encoding heterologous polypeptides, host cells transformed with daf fusion dna, and daf fusion proteins
DE3382760D1 (de)	1994-11-17	Herstellung von funktionellen menschlichen Urokinasepolypeptiden.
ES8603957A1 (es)	1986-01-16	Procedimiento para obtener una proteina heterologa para levadura
ES8802440A1 (es)	1988-06-01	Un metodo para preparar una particula que puede ser empleada como vacuna contra la infeccion por hepatitis b
DK595286A (da)	1987-06-13	Fremgangsmaade til fremstilling af thrombininhibitorer
ATA192895A (de)	1998-07-15	Herstellung von proteinen aus pro-proteinen durch fusionsproteine abgeleitet von furin oder furinanalogen
FI922204A0 (fi)	1992-05-14	Proteinkomplex med faktor viii:c- aktivitet och framstaellning av desamma.
DE3884565D1 (de)	1993-11-04	Hefe-expressionssystem.
ES2080759T3 (es)	1996-02-16	Produccion de proteinas o polipeptidos fusionados.
FI861559L (fi)	1986-10-16	Menetelmä hepatitis B-viruksen pinta-antigeenin PreS1-PreS2-S-proteiinin koodaavan alueen koodaamia proteiineja käsittävän proteiinin valmistamiseksi sekä menetelmässä käytettävät yhdistelmä-DNA-vektorit ja -kontameerit sekä nisäkässolut
FI934079L (fi)	1993-09-17	Menetelmä fuusioproteiinin valmistamiseksi

Legal Events

Date	Code	Title	Description
1995-03-01	FG3A	Patent granted, date of granting	Effective date: 19940809
1999-07-30	PC3A	Transfer or assignment	Free format text: 19990329 DSM N.V. NL
2005-10-31	PC3A	Transfer or assignment	Owner name: DSM IP ASSETS B. V., NL Effective date: 20050823
2008-02-27	PD4A	Change of proprietorship	Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC., US Effective date: 20080215
2009-08-17	MM4A	Annulment/lapse due to non-payment of fees, searched and examined patent	Free format text: MAXIMUM VALIDITY LIMIT REACHED Effective date: 20090809